激素避孕药与脑膜瘤风险:瑞典注册库病例对照研究
该研究基于瑞典国家注册库,纳入2007-2015年确诊的1055例20岁以上女性脑膜瘤病例,按出生年和居住县匹配选取对照,分析激素避孕药与脑膜瘤的关联。结果显示,使用含甲羟孕酮的注射类避孕药与脑膜瘤风险显著相关(OR=5.49,95%CI 4.51-6.67),其他孕激素类避孕药关联较弱(OR=1.34,95%CI 1.09-1.65),宫内节育器、阴道环及皮下埋植剂未见关联。
要点
- 含甲羟孕酮的注射类避孕药与脑膜瘤风险显著相关(OR=5.49)。
- 其他孕激素类避孕药关联较弱(OR=1.34),非激素或局部避孕方式未见关联。
- 使用甲羟孕酮每年每万例暴露女性约增加2例脑膜瘤。
核心结论
- 含甲羟孕酮的注射类激素避孕药与脑膜瘤风险存在强关联,提示其可能对脑膜瘤生长有因果作用。
研究设计与样本
- 基于瑞典国家注册库的病例对照研究,纳入2007-2015年确诊的1055例20岁以上女性脑膜瘤病例,按出生年和居住县匹配随机选取20倍对照。
主要发现
- 使用激素避孕药≥1年者脑膜瘤OR为1.76(95%CI 1.53-2.03)。
- 含甲羟孕酮避孕药OR为5.49(95%CI 4.51-6.67),其他孕激素类OR为1.34(95%CI 1.09-1.65)。
- 宫内节育器、阴道环及皮下埋植剂与脑膜瘤无关联。
- 使用甲羟孕酮每年每万例暴露女性约增加2例脑膜瘤。
临床怎么用
- 对脑膜瘤患者或有脑膜瘤病史的女性,应评估含甲羟孕酮注射避孕药的使用并考虑替代方案。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Studies of hormonal contraceptives and the risk of meningioma has often relied on self-reported information, primarily focusing on oral contraceptives. Recently, an association between progestins and meningioma was suggested. We aimed to analyze the association between hormonal contraceptives and meningioma using data from Swedish national registries. METHODS: We used the Swedish Cancer Register to identify women born 1955-1995, diagnosed with meningioma at age ≥20 years, between 2007 and 2015 (N = 1055). Twenty controls per case were randomly selected from the Swedish population register, matched by birth year and county of residence. We retrieved information regarding prescriptions of hormonal contraceptives from the National Prescribed Drug Register. Adjusted conditional logistic regression models were used to evaluate the association between hormonal contraceptive use and meningioma occurrence. RESULTS: Women prescribed hormonal contraceptives ≥1 year before the index date had an odds ratio (OR) of meningioma of 1.76 (95% CI, 1.53-2.03). For contraceptives containing medroxyprogesterone the OR was 5.49 (95% CI, 4.51-6.67), while the association was weaker for other progesterone contraceptives (OR = 1.34, 95% CI, 1.09-1.65). No association was found for intrauterine devices, vaginal rings, and subdermal implants. CONCLUSIONS: This large register-based case-control study show a strong association between injectable hormonal contraceptives containing medroxyprogesterone and meningioma risk. The results add to the growing body of evidence of an association between meningiomas and progestins in general and the strong, consistent associations suggest a causal role of injectable medroxyprogesterone in meningioma growth. Our results correspond to 2 additional cases of meningioma per 10 000 women exposed to medroxyprogesterone per year.
引用
- Tettamanti G, Shu X, Mogensen H, et al. Hormonal contraceptives and the risk of meningioma: A Swedish register-based case-control study. Neuro Oncol. 2026. PMID: 41056434. doi:10.1093/neuonc/noaf228
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。